IL31926A - 17beta-ethers of 1alpha,2alpha-methylene-19-nor-testosterone and of its 18-alkyl homologues - Google Patents
17beta-ethers of 1alpha,2alpha-methylene-19-nor-testosterone and of its 18-alkyl homologuesInfo
- Publication number
- IL31926A IL31926A IL31926A IL3192669A IL31926A IL 31926 A IL31926 A IL 31926A IL 31926 A IL31926 A IL 31926A IL 3192669 A IL3192669 A IL 3192669A IL 31926 A IL31926 A IL 31926A
- Authority
- IL
- Israel
- Prior art keywords
- ethers
- melting point
- 2alpha
- 17beta
- 1alpha
- Prior art date
Links
- 229960004719 nandrolone Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 11
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 10
- 150000002170 ethers Chemical class 0.000 description 8
- 230000001195 anabolic effect Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229910001923 silver oxide Inorganic materials 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000001548 androgenic effect Effects 0.000 description 3
- 230000031709 bromination Effects 0.000 description 3
- 238000005893 bromination reaction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- HETCEOQFVDFGSY-UHFFFAOYSA-N Isopropenyl acetate Chemical compound CC(=C)OC(C)=O HETCEOQFVDFGSY-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001440 androstane derivatives Chemical class 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19681768161 DE1768161B2 (de) | 1968-04-05 | 1968-04-05 | Aether des 1 alpha, 2 alpha-methylen-19-nor-testosterons und seiner 18- alkylhomologen, verfahren zu ihrer herstellung, diese enthaltende arzneimittel sowie entsprechende 5 alpha-oestran-zwischenprodukte |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL31926A0 IL31926A0 (en) | 1969-05-28 |
| IL31926A true IL31926A (en) | 1973-06-29 |
Family
ID=5699619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL31926A IL31926A (en) | 1968-04-05 | 1969-03-30 | 17beta-ethers of 1alpha,2alpha-methylene-19-nor-testosterone and of its 18-alkyl homologues |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US3590033A (ja) |
| AT (2) | AT289308B (ja) |
| BE (1) | BE731081A (ja) |
| CH (1) | CH535219A (ja) |
| CS (3) | CS162678B2 (ja) |
| DE (1) | DE1768161B2 (ja) |
| DK (1) | DK119109B (ja) |
| ES (1) | ES365404A1 (ja) |
| FI (1) | FI45320C (ja) |
| FR (1) | FR2007402A1 (ja) |
| GB (1) | GB1265393A (ja) |
| IE (1) | IE32768B1 (ja) |
| IL (1) | IL31926A (ja) |
| NL (1) | NL160571C (ja) |
| NO (1) | NO129348B (ja) |
| SE (1) | SE344063B (ja) |
-
1968
- 1968-04-05 DE DE19681768161 patent/DE1768161B2/de active Granted
-
1969
- 1969-03-11 CH CH366869A patent/CH535219A/de not_active IP Right Cessation
- 1969-03-17 DK DK143669AA patent/DK119109B/da unknown
- 1969-03-21 AT AT922969A patent/AT289308B/de not_active IP Right Cessation
- 1969-03-21 AT AT282269A patent/AT290743B/de not_active IP Right Cessation
- 1969-03-24 CS CS2074A patent/CS162678B2/cs unknown
- 1969-03-24 CS CS741410A patent/CS162680B2/cs unknown
- 1969-03-24 CS CS741409A patent/CS162679B2/cs unknown
- 1969-03-28 ES ES365404A patent/ES365404A1/es not_active Expired
- 1969-03-30 IL IL31926A patent/IL31926A/en unknown
- 1969-03-31 SE SE4540/69A patent/SE344063B/xx unknown
- 1969-03-31 GB GB1265393D patent/GB1265393A/en not_active Expired
- 1969-04-01 NO NO01365/69A patent/NO129348B/no unknown
- 1969-04-01 FI FI690958A patent/FI45320C/fi active
- 1969-04-01 IE IE443/69A patent/IE32768B1/xx unknown
- 1969-04-03 NL NL6905323.A patent/NL160571C/xx not_active IP Right Cessation
- 1969-04-04 BE BE731081D patent/BE731081A/xx unknown
- 1969-04-04 FR FR6910486A patent/FR2007402A1/fr not_active Withdrawn
- 1969-04-04 US US815259A patent/US3590033A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GB1265393A (ja) | 1972-03-01 |
| NO129348B (ja) | 1974-04-01 |
| DK119109B (da) | 1970-11-16 |
| IE32768L (en) | 1969-10-05 |
| DE1768161A1 (de) | 1971-11-18 |
| FI45320C (fi) | 1972-05-10 |
| FR2007402A1 (ja) | 1970-01-09 |
| AT290743B (de) | 1971-06-11 |
| BE731081A (ja) | 1969-10-06 |
| US3590033A (en) | 1971-06-29 |
| DE1768161B2 (de) | 1977-06-23 |
| CS162678B2 (ja) | 1975-07-15 |
| CS162679B2 (en) | 1975-07-15 |
| NL160571B (nl) | 1979-06-15 |
| IL31926A0 (en) | 1969-05-28 |
| FI45320B (ja) | 1972-01-31 |
| NL6905323A (ja) | 1969-10-07 |
| AT289308B (de) | 1971-04-13 |
| NL160571C (nl) | 1979-11-15 |
| SE344063B (ja) | 1972-03-27 |
| IE32768B1 (en) | 1973-11-28 |
| CS162680B2 (en) | 1975-07-15 |
| ES365404A1 (es) | 1971-01-01 |
| CH535219A (de) | 1973-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3318926A (en) | 7alpha-methyl-16alpha-hydroxy-estrones | |
| US3679714A (en) | 17{60 ,21-dimethyl-19-nor-{66 {11 {11 {11 -pregnadiene-3,20-dione and process therefor | |
| Hallsworth et al. | 924. Aspects of stereochemistry. Part VII. Metal reduction of vicinal epoxycyclohexanes | |
| WO2020182228A1 (zh) | 一种牛磺胆酸钠的精制方法 | |
| US3190880A (en) | 17-tetrahydropyranyl ethers of androstanes | |
| IL31926A (en) | 17beta-ethers of 1alpha,2alpha-methylene-19-nor-testosterone and of its 18-alkyl homologues | |
| US3084159A (en) | 3-enol ethers of 3-oxo-delta-6-aminomethyl steroids and process for preparing same | |
| US3904599A (en) | Cardenolide-3-(2'-desoxy-glycosides)+0 and process for their manufacture | |
| IL32973A (en) | 18-methyl-17beta-hydroxy-17alpha-ethynyl-4,6-dichloro-delta 4,6-oestradien-3-one and derivatives thereof | |
| US3184383A (en) | New derivative of gitoxin, the use and preparation thereof | |
| US3238197A (en) | 19-nor-20-spiroxa-4, 9(10)-dien-3-one, the corresponding 3, 21-dione and intermediates therefor | |
| US3838146A (en) | Cardenolide-and bufadienolide-3-(2',3'-didesoxyglycosides)and processfor their preparation | |
| US3377366A (en) | 17alpha-alkynyl/alkenyl-11, 13beta-dialkylgon-5(10)-en-3-ones and esters thereof | |
| US2915433A (en) | 16-methylene-17beta-(alpha, beta-oxido-propanoyl)-androstenes | |
| US3167547A (en) | 17-tetrahydropyranyl ethers of 19-nor, 3-keto androstanes | |
| JP2631688B2 (ja) | グリチルレチン酸誘導体からなる医薬品 | |
| US3127314A (en) | Method of reducing hyperlipemia by | |
| US3469008A (en) | Medicinal compositions which contain 15,16beta-methylene steroids of the 19 nor-androstane series | |
| US3574690A (en) | Delta 4,9,11-gonatriene-3-ones | |
| US3394150A (en) | Polynitrates of steroidal alcohols | |
| US3496168A (en) | 4-alkoxyestradiols | |
| US3567713A (en) | Derivatives of 2alpha,3alpha-epithioandrostane and process for preparing them | |
| US3511871A (en) | Glycyrrhetinic acid derivatives | |
| US3127427A (en) | 10-alkenyl-steroids and process therefor | |
| US3474115A (en) | Water soluble aldosterone like agents |